Sophiris Bio Inc. (SPHS) Trading Up 4.1%
Sophiris Bio Inc. (NASDAQ:SPHS)’s share price was up 4.1% during trading on Tuesday . The stock traded as high as $3.08 and last traded at $3.02, with a volume of 1,314,244 shares changing hands. The stock had previously closed at $2.90.
Several equities analysts have recently commented on SPHS shares. Piper Jaffray Cos. began coverage on Sophiris Bio in a research note on Tuesday, August 30th. They set an “overweight” rating and a $7.00 target price for the company. Roth Capital began coverage on Sophiris Bio in a research report on Thursday, September 15th. They set a “buy” rating and a $8.00 price target on the stock. Maxim Group reissued a “buy” rating and set a $4.00 price target on shares of Sophiris Bio in a research report on Friday, June 10th. Finally, Echelon Wealth Partners reissued a “buy” rating and set a $5.00 price target on shares of Sophiris Bio in a research report on Friday, June 10th.
The firm has a 50 day moving average of $4.04 and a 200 day moving average of $2.42. The company’s market cap is $68.76 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/sophiris-bio-inc-sphs-trading-up-4-1.html
An institutional investor recently raised its position in Sophiris Bio stock. Citadel Advisors LLC raised its position in shares of Sophiris Bio Inc. (NASDAQ:SPHS) by 65.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,176 shares of the biopharmaceutical company’s stock after buying an additional 19,402 shares during the period. Citadel Advisors LLC owned 0.23% of Sophiris Bio worth $106,000 at the end of the most recent quarter. 5.29% of the stock is owned by institutional investors.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.